Browsing by Author "Mittal, Anupama"

Now showing 1 - 20 of 70

2, 2-Bis (hydroxymethyl) propionic acid based cyclic carbonate monomers and their (co) polymers as advanced materials for biomedical applications
(Elsevier, 2021-08) Chitkara, Deepak; Mittal, Anupama
Designing grafted biodegradable polymers with tailored multi-functional properties is one of the most researched fields with extensive biomedical applications. Among many biodegradable polymers, polycarbonates have gained much attention due to their ease of synthesis, high drug loading, and excellent biocompatibility profiles. Among various monomers, 2,2-bis(hydroxymethyl) propionic acid (bis-MPA) derived cyclic carbonate monomers have been extensively explored in terms of their synthesis as well as their polymerization. Since the late 90s, significant advancements have been made in the design of bis-MPA derived cyclic carbonate monomers as well as in their reaction schemes. Currently, bis-MPA derived polycarbonates have taken a form of an entire platform with a multitude of applications, the latest being in the field of nanotechnology, targeted drug, and nucleic acid delivery. The present review outlines an up to date developments that have taken place in the last two decades in the design, synthesis, and biomedical applications of bis-MPA derived cyclic carbonates and their (co)polymers
Advancements in Polymeric Systems for Nucleic Acid Delivery
(CRC Press, 2018) Chitkara, Deepak; Mittal, Anupama
RNA interference (RNAi) has been suggested as a potential treatment method to improve current chemotherapeutic regimens. It is a sequence-specific, post-transcriptional gene silencing mechanism in animals and plants that targets mRNA encoded by the mutant gene. RNA-based strategies are useful in targeting the mutations that results in a gain of function wherein RNA levels are modified and includes the use of antisense oligonucleotide, triplex-forming oligonucleotides, aptamers, trans-splicing, segmental trans-splicing, ribozymes, DNAzymes, siRNA, and miRNA (Chitkara, Singh, & Mittal, 2016). Among these, siRNA and miRNA have generated a lot of interest as they could be easily synthesized, do not require genome integration, and thus could curtail potential problems of insertional mutagenesis. These are 20–25 base pair-long RNA oligonucleotides that are incorporated into the pre-RISC (RNA-induced
Asiaticoside polymeric nanoparticles for effective diabetic wound healing through increased collagen biosynthesis: In-vitro and in-vivo evaluation
(Elsevier, 2023-01) Chitkara, Deepak; Mittal, Anupama
Asiaticoside (AST) is a naturally available phytoconstituent that enables effective wound healing mainly by promoting collagen biosynthesis. However, the physicochemical nature of AST such as high molecular weight (959.12 g/mol), poor water solubility and poor permeability limits its therapeutic effects. This study aims to develop Asiaticoside polymeric nanoparticles (AST PNP) embedded in a gelatin based biodegradable hydrogel (15 % w/v) for application in the wound cavity to enable sustained release of AST and enhance its therapeutic effects. The AST PNP were fabricated in the desired size range (168.4 nm; PDI (0.09)) and the morphology, rate of fluid uptake, rate of water loss, and water vapor transmission rate of AST PNP incorporated hydrogel were determined. AST PNP gel showed porous structural morphology and possessed ideal characteristics as a graft for wound healing. The drug release kinetics and cellular uptake of AST PNP were investigated wherein, AST PNP demonstrated sustained release profile upto 24 h in comparison to free AST (complete release within 6 h) and exhibited an enhanced intra-cellular uptake in fibroblasts within 3 h compared to the free drug. In-vitro cell culture studies also demonstrated significant proliferation and migration of fibroblasts in the presence of AST PNP. Additionally, AST PNP gel upon application to the wounds of diabetic rats depicted improved wound healing efficacy in terms of improved collagen biosynthesis, upregulated COL-1 protein level (∼1.85 fold vs free AST), and enhanced expression of α-SMA compared to control groups. Altogether, formulation of AST as polymeric nanoparticles in a gel based carrier offered significant improvement in the therapeutic properties of AST for the management of diabetic wounds.
Belinostat loaded lipid–polymer hybrid nanoparticulate delivery system for breast cancer: improved pharmacokinetics and biodistribution in a tumor model
(RSC, 2023-10) Chitkara, Deepak; Mittal, Anupama
Despite various treatment modalities for breast cancer, it still persists as one of the most diagnosed types of cancer in females. The recent investigations in the epigenetics of breast cancer reveal several aberrations in the expression levels of various HDAC enzymes. Henceforth, the present work entails the formulation and characterization of a lipid polymer-based hybrid nanoparticulate (LPN) system for delivery of an epigenetic modulator drug, Belinostat, for its clinical application in breast cancer. The size of Belinostat nanoparticles prepared using a modified hot homogenization method was found to be 166.6 ± 19.95 nm with an encapsulation efficiency of 94.5 ± 5.1%. In vitro characterization for cytotoxicity, cellular uptake, and protein expression in two different breast cancer cells, 4T1 and MCF 7, revealed the superiority of the formulation in comparison with the free drug in MCF 7 cells. Subsequently, the behaviour of the formulation in in vivo settings of healthy and breast cancer xenograft bearing animals was analyzed using pharmacokinetic and biodistribution studies. The results revealed that the formulation demonstrated multi-fold improvement in the pharmacokinetic parameters in tumor bearing animals when compared with the free drug while no difference in pharmacokinetic behaviour was observed in healthy animals indicating the altered biodistribution and specificity of the formulation in breast tumor. This was confirmed by the biodistribution studies exhibiting 20-fold improved uptake and retention of the nanoparticulate formulation in tumor tissues of the animal model at the end of 4 h. Thus, the developed LPN system holds potential to act as a novel drug delivery system for Belinostat with several advantages over the free drug.
Biodegradable polymers for emerging clinical use in tissue engineering
(Wiley, 2011-05) Mittal, Anupama
A large fraction of the total health-care costs worldwide can be attributed to tissue loss or organ failure due to congenital or acquired diseases, accidents, or trauma. These costs are not only of monetary value but, more importantly, of value in human life and quality of life. The current demands for transplant organs and tissues, however, is far outpacing the supply, and all manner of projections indicate that this gap will continue to widen [1]. Thus, there has been an urgent demand for more successful regenerative strategies to repair or replace damaged tissues and organs. Tissue engineering is a thriving new area of multidisciplinary research that has potential to revolutionize the treatment of diseased and damaged tissues or organs. The ability to develop materials that can interface with tissues structurally, mechanically, and biofunctionally is important to the success of regenerative strategies [2]. As a new and multidisciplinary endeavor, tissue engineering holds the promises of (a) eliminating reoperations by using biological substitutes,(b) using biological substitutes to solve problems of implant rejection, transmission of diseases associated with xenografts, and the shortage in organ donations,(c) providing long-term solutions in tissue repair or treatment of diseases, and (d) potentially offering treatments for medical conditions that are currently untreatable [3]. The approaches to construction of any tissue or organ typically rely on three essential components: cells, which will ultimately form the new tissue; scaffolds, designed to maintain the cells in a three-dimensional environment at the implantation site; and signals that guide the gene expression
Can breakthroughs in dermal and transdermal macromolecule delivery surmount existing barriers and revolutionize future therapeutics?
(Springer, 2025-05) Mittal, Anupama; Chitkara, Deepak
The delivery of macromolecules through dermal and transdermal routes presents both significant challenges and transformative opportunities in therapeutic applications. This review highlights the most recent advancements and innovative strategies aimed at overcoming the barriers associated with macromolecular delivery. Cutting-edge approaches such as the use of adjuvants (e.g., hyaluronic acid-based and chemical penetration enhancers), bioactive peptides with diverse functionalities, and mechanical force techniques—including iontophoresis, microneedles, and electroporation—are thoroughly explored. While various strategies have been implemented to enhance skin delivery, they often present significant challenges, particularly for macromolecules. Addressing these challenges requires integrating novel technologies and understanding the interplay between biological barriers and delivery mechanisms. Furthermore, the role of nanotechnology, through systems like nanoemulsions, polymeric nanoparticles, and transferosomes, is examined for its ability to protect macromolecules and regulate their release. Notably, this review provides unique perspectives on the interplay between these strategies and their potential to revolutionise future therapeutics. By highlighting key trends and advancements in macromolecule delivery, this review underscores the importance of innovative approaches in overcoming existing barriers and enabling efficient drug administration.
Cationic lipopolymeric nanoplexes containing the CRISPR/Cas9 ribonucleoprotein for genome surgery
(RSC, 2022-07) Chitkara, Deepak; Mittal, Anupama
sgRNA/Cas9 ribonucleoproteins (RNPs) provide a site-specific robust gene-editing approach avoiding the mutagenesis and unwanted off-target effects. However, the high molecular weight (∼165 kDa), hydrophilicity and net supranegative charge (∼−20 mV) hinder the intracellular delivery of these RNPs. In the present study, we have prepared cationic RNPs lipopolymeric nanoplexes that showed a size of 117.3 ± 7.64 nm with +6.17 ± 1.04 mV zeta potential and >90% entrapment efficiency of RNPs. Further, these RNPs lipopolymeric nanoplexes showed good complexation efficiency and were found to be stable for 12 h with fetal bovine serum. These RNPs lipopolymeric nanoplexes did not induce any significant cytotoxicity in HEK293T cells, and were efficiently uptaken via a clathrin-mediated pathway with optimal transfection efficiency and nuclear localization after 48 h. Further, HEK293T cells having the mGFP insert were used as a cell line model for gene editing, wherein the loss of the mGFP signal was observed as a function of gene editing after transfection with mGFP targeting RNPs lipopolymeric nanoplexes. Further, the T7 endonuclease and TIDE assay data showed a decent gene editing efficiency. Additionally, the lipopolymeric nanoplexes were able to transfect muscle cells in vivo, when injected intra-muscularly. Collectively, this study explored the potential of cationic lipopolymeric nanoplexes for delivering gene-editing endonucleases.
Cholesterol and Morpholine Grafted Cationic Amphiphilic Copolymers for miRNA-34a Delivery
(ACS, 2018-05) Chitkara, Deepak; Mittal, Anupama
miR-34a is a master tumor suppressor playing a key role in the several signaling mechanisms involved in cancer. However, its delivery to the cancer cells is the bottleneck in its clinical translation. Herein we report cationic amphiphilic copolymers grafted with cholesterol (chol), N,N-dimethyldipropylenetriamine (cation chain) and 4-(2-aminoethyl)morpholine (morph) for miR-34a delivery. The copolymer interacts with miR-34a at low N/P ratios (∼2/1) to form nanoplexes of size ∼108 nm and a zeta potential ∼ +39 mV. In vitro studies in 4T1 and MCF-7 cells indicated efficient transfection efficiency. The intracellular colocalization suggested that the copolymer effectively transported the FAM labeled siRNA into the cytoplasm within 2 h and escaped from the endo-/lysosomal environment. The developed miR-34a nanoplexes inhibited the breast cancer cell growth as confirmed by MTT assay wherein 28% and 34% cancer cell viability was observed in 4T1 and MCF-7 cells, respectively. Further, miR-34a nanoplexes possess immense potential to induce apoptosis in both cell lines.
Coenzyme Q10 loaded lipid-polymer hybrid nanoparticles in gel for the treatment of psoriasis like skin condition
(Elsevier, 2022-10) Chitkara, Deepak; Mittal, Anupama
Psoriasis is characterized by severe dermal inflammation caused by pre-oxidants that dominate the skin's antioxidant system. The available therapeutic strategies seeks betterment in terms of cost effectiveness, long-term usage and safety. This research work highlights the use of monolithic polymer-lipid hybrid nanoparticles to deliver coenzyme Q10, a prominent antioxidant and anti-inflammatory biomolecule, to the skin. The system has both polymeric and lipidic characteristics, so each could compensate the other's shortcomings. The particle size, polydispersity index, and encapsulation efficiency of the nanoformulation were found to be 121 ± 11.61 nm, 0.252 ± 0.073, and 78.57 ± 3.88%, respectively, when produced employing the hot homogenization technique. The nanoparticles released CoQ10 steadily and consistently for up to 3 days. Further, the nanoformulation was used as a topical gel (CoQ10–0.06% w/w), and demonstrating non-newtonian rheological characteristics. An imiquimod-induced psoriatic mouse model was used to evaluate the in vivo efficacy of the nanoformulation gel, which produced a significant increase in CoQ10 efficacy when applied topically compared to free CoQ10 gels. Overall, the CoQ10 loaded NanoHybrid gel was found to be efficient for the in vivo application for the treatment of psoriasis like skin conditions.
Core-shell nanoparticulate formulation of gemcitabine: lyophilization, stability studies, and in vivo evaluation
(Springer, 2014-10) Chitkara, Deepak; Mittal, Anupama
Core-shell nanoparticulate formulation of gemcitabine was prepared by incorporating gemcitabine in a hydrophilic bovine serum albumin (BSA) core surrounded by hydrophobic poly(dl-lactic acid-co-glycolic acid) (PLGA) shell with a particle size of 243 nm and encapsulation efficiency of 40.5 %. Prepared formulations were lyophilized, wherein several cryoprotectants were screened for product attributes such as cake appearance, reconstitution with water, and size constancy. Trehalose was screened as a lyoprotectant, which showed stability for 6 months at 5 °C and 25 °C/60 % relative humidity (RH) conditions. However, an increase in particle size was observed at accelerated conditions (40 °C/75 % RH). In vitro evaluation of these nano-formulations in MCF-7 breast cancer cells showed enhanced cellular uptake (90 %) as compared to GEMCITE® uptake (51 %) in 6 h along with reduced IC50 value at 72 h (16 μM versus 30 μM). In vivo studies in Sprague Dawley rats showed C max, t 1/2, and area under the curve (AUC) at 2.55 μg/ml, 13.6 h, and 28,322.5 μg/l/h, respectively, whereas GEMCITE® at the same dose showed significantly lower corresponding values at 1.94 μg/ml, 6.89 h, and 13,967 μg/l/h. In the same study, AUC and C max of inactive metabolite of gemcitabine (dFdU) were reduced by 33 and 42 %, respectively, for these nanoparticles compared to GEMCITE®. In 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer model, significantly reduced tumor growth was observed in gemcitabine-loaded-nanoparticle-treated animals compared with GEMCITE®-treated animal at equivalent dose (121 versus 243 % in 30 days). The results indicated that our core-shell nanoparticles are more effective for tumor reduction compared to marketed formulation of gemcitabine, GEMCITE®.
cRGD-functionalized nanohybrid conjugates codelivering temozolomide and rapamycin for treating Glioblastoma multiforme: in vitro and in vivo evaluation
(ACS, 2025-10) Mittal, Anupama; Chitkara, Deepak
The conventional treatment of glioblastoma multiforme primarily uses Temozolomide as a chemoadjuvant alongside debulking surgery and radiotherapy; however, resistance, as well as tumor recurrence, remains a common outcome. Employing combination therapy to target multiple pathways while improving delivery with advanced systems has always been sought after. Herein, we report cRGD-functionalized hybrid polymeric nanoconjugates that could deliver Temozolomide (TMZ) and rapamycin (RAP) (cRGD-Hybrid TMZ/R NCs) as a dual payload. The cRGD-Hybrid TMZ/R NCs were thoroughly characterized, exhibiting a particle size and surface zeta potential of 141.83 nm (PDI 0.233) and −0.168 mV, respectively. The nanoconjugates carrying TMZ and RAP as dual payloads were initially screened for synergism by determining their combination index in C6 and U87MG glioma cells. Further, in vitro cell-based assays showed improved cellular uptake, cytotoxicity, and apoptotic potential of hybrid nanoconjugates. Thereafter, the cRGD-Hybrid TMZ/R NCs were evaluated in a C6-cell-induced syngeneic orthotropic glioma model in Sprague–Dawley rats, exhibiting an improved therapeutic outcome including, reduced hemispherical width (RH/LH) ratios, tumor burden, and improved survival rates compared to the free drug(s) counterpart. The histopathological evaluation indicated no major sign of toxicity in vital organs such as heart, lungs, liver, kidney, and spleen, affirming the biocompatibility of the developed cRGD-Hybrid TMZ/R nanoconjugates. In conclusion, amalgamating the cRGD cell-penetrating peptide with polymer hybrid nanoconjugates presents a better approach for delivering multiple payloads in the treatment of GBM.
CRISPR/Cas System for Genome Editing: Progress and Prospects as a Therapeutic Tool
(American Society for Pharmacology and Experimental Therapeutics, 2019-09) Mittal, Anupama; Chitkara, Deepak
CRISPR was first observed in 1987 in bacteria and archaea and was later confirmed as part of bacterial adaptive immunity against the attacking phage. The CRISPR/Cas restriction system involves a restriction endonuclease enzyme guided by a hybrid strand of RNA consisting of CRISPR RNA and trans-activating RNA, which results in gene knockout or knockin followed by nonhomologous end joining and homology-directed repair. Owing to its efficiency, specificity, and reproducibility, the CRISPR/Cas restriction system was said to be a breakthrough in the field of biotechnology. Apart from its application in biotechnology, CRISPR/Cas has been explored for its therapeutic potential in several diseases including cancer, Alzheimer’s disease, sickle cell disease, Duchenne muscular dystrophy, neurologic disorders, etc., wherein CRISPR/Cas components such as Cas9/single guide RNA (sgRNA) ribonucleoprotein, sgRNA/mRNA, and plasmid were delivered. However, limitations including immunogenicity, low transfection, limited payload, instability, and off-target binding pose hurdles in its therapeutic use. Nonviral vectors (including cationic polymers, lipids, etc.), classically used as carriers for therapeutic genes, were used to deliver CRISPR/Cas components and showed interesting results. Herein, we discuss the CRISPR/Cas system and its brief history and classification, followed by its therapeutic applications using current nonviral delivery strategies.
Curcumin loaded biomimetic composite graft for faster regeneration of skin in diabetic wounds
(Elsevier, 2018-10) Mittal, Anupama
Diabetic wounds do not heal in an organized and timely manner due to poor blood glucose control and weakened immune system. In the present study, wound healing properties of curcumin were explored by designing and evaluating a biomimetic composite graft for skin regeneration in diabetic wounds. Curcumin was incorporated in gelatin solution by nanoprecipitation method in particle size of 311.3 ± 35.1 nm. Cytomodulin coupled porous PLGA microparticles (cPMS) were prepared, dispersed in curcumin loaded gelatin solution and cross-linked with glutaraldehyde (GTA) to form a composite graft (Gel-Cur-cPMS). Under SEM, cPMS showed porous structure and Gel-Cur(1%w/v)-cPMS(1%w/v) indicated interconnecting pores of gelatin hydrogel. Formulation stability at the application site was indicated by micro shrinkage temperature. Gel-Cur(1%w/v)-cPMS(1%w/v) absorbed 40% of additional fluid weight of its own weight and demonstrated a sustained release of the curcumin over a period of 7 days. Evaluation of wound healing properties of the composite graft in diabetic wound model indicated 75%, 68% and 63% of wound closure with Gel-Cur(1%w/v)-cPMS(1%w/v), Gel-Cur(1%w/v) and untreated control group respectively. Gel-Cur(1%w/v)-cPMS(1%w/v) demonstrated better and faster wound healing visually along with regenerating a skin of higher tensile strength than Gel-Cur(1%w/v) treated and untreated control group. These results demonstrate that the curcumin-loaded composite graft bears potential as a skin graft with wound healing properties in diabetic wounds.
Cytomodulin-functionalized porous PLGA particulate scaffolds respond better to cell migration, actin production and wound healing in rodent model
(Wiley, 2012-06) Mittal, Anupama
In the present study, porous PLGA microparticulate scaffolds (PMS_P), surface-hydrolysed scaffolds (PMS_Hyd) and cytomodulin-coupled scaffolds (PMS_CM) were prepared and characterized. After coupling the particles with cytomodulin, the size was reduced from 334 µm (span 0.53) to 278 µm due to hydrolysis, and contact angle also decreased from 70.87 ± 8.56 to 31.43 ± 7.43, indicating an increase in hydrophilicity. Surface roughness and pore density increased, along with an increase in surface area from 9.59 ± 0.36 to 16.82 ± 0.064 m2/g after attaching the biomolecule CM onto the PLGA particles. In vitro cell culture experiments on human dermal fibroblasts (HDFs) were performed for 21 days, in which MTT assay indicated two-fold higher cell proliferation on PMS_Hyd than on PMS_CM; however, cell distribution, cell spreading and actin production were significantly higher on PMS_CM than on other scaffolds. Migration of cells from PMS_CM to a 2D plate was gradual but the migrated cells attained early confluence, indicating the preservation of normal cellular functions. In a full-thickness wound mouse model, PMS_CM exhibited 80% wound closure within 2 weeks. Further, at the end of week 3, the inflammatory cell count in the PMS_CM group was reduced to one-third of the control group, while in PMS_P and PMS_Hyd the extent of inflammation was much higher and more severe. In the case of PMS_CM, abundant fibroblast proliferation, early formation of the scar tissue, eschar formation and inward movement of the wound margins (a zipper-like movement) towards the deeper layers of the skin suggested advanced wound healing. Cytomodulin-coupled scaffolds ensured better cell spreading and migration and thus enabled rapid wound healing
Delhi's network for surveillance of antimicrobial resistance: The journey, challenges and output from first year
(Elsevier, 2023-02) Mittal, Anupama
Antimicrobial resistance [AMR] has emerged as a global and national priority and establishing an effective surveillance system for antimicrobial resistance is an essential prerequisite for generating evidence for informed policymaking at both national and state levels.
Delivery strategies for CRISPR/Cas genome editing tool for retinal dystrophies: challenges and opportunities
(Elsevier, 2022-03) Chitkara, Deepak; Mittal, Anupama
CRISPR/Cas, an adaptive immune system in bacteria, has been adopted as an efficient and precise tool for site-specific gene editing with potential therapeutic opportunities. It has been explored for a variety of applications, including gene modulation, epigenome editing, diagnosis, mRNA editing, etc. It has found applications in retinal dystrophic conditions including progressive cone and cone-rod dystrophies, congenital stationary night blindness, X-linked juvenile retinoschisis, retinitis pigmentosa, age-related macular degeneration, leber's congenital amaurosis, etc. Most of the therapies for retinal dystrophic conditions work by regressing symptoms instead of reversing the gene mutations. CRISPR/Cas9 through indel could impart beneficial effects in the reversal of gene mutations in dystrophic conditions. Recent research has also consolidated on the approaches of using CRISPR systems for retinal dystrophies but their delivery to the posterior part of the eye is a major concern due to high molecular weight, negative charge, and in vivo stability of CRISPR components. Recently, non-viral vectors have gained interest due to their potential in tissue-specific nucleic acid (miRNA/siRNA/CRISPR) delivery. This review highlights the opportunities of retinal dystrophies management using CRISPR/Cas nanomedicine.
Development of quercetin nanoformulation and in vivo evaluation using streptozotocin induced diabetic rat model
(Springer, 2012-02) Chitkara, Deepak; Mittal, Anupama
Quercetin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Qu-NP) were prepared by emulsion–diffusion–evaporation method and characterized as 179.9 ± 11.2 nm in size with 0.128 as polydispersity index, more than 86% drug entrapment efficiency, and zeta potential was −6.06 ± 1.51 mV. d-Trehalose (5% w/v) was found to be a suitable cryoprotectant for lyophilization of Qu-NP, and antioxidant assays indicated that Qu-NP were able to retain the antioxidant property similar to that of free drug at equivalent concentration after formulation development. In vitro release study of Qu-NP showed a controlled release pattern of quercetin. An enhanced oral bioavailability (523% relative increase) was observed in pharmacokinetic study with a 6-day sustained release from Qu-NP as compared to quercetin suspension, which indicated the reduced dosing frequency. Efficacy in diabetic rats suggested that same dose of Qu-NP on every fifth day was sufficient to bring effect similar to daily dose of oral quercetin suspension, and the same effect was also observed for catalase and superoxide dismutase levels in pancreas and kidneys. Thus, the system offers an efficacious oral therapy with reduced dose and dosing frequency for treatment of diabetes and is hence patient compliant.
Docetaxel and alpha-lipoic acid co-loaded nanoparticles for cancer therapy
(Future Science Group, 2019-04) Chitkara, Deepak; Mittal, Anupama
The current study aims to co-deliver docetaxel (DTX) and alpha-lipoic acid (ALA) using solid lipid nanoparticles (SLNs) as a carrier for the treatment of breast cancer. Methods: Computational analysis was used to screen different solid lipids as carriers, following which SLNs were prepared and characterized. Furthermore, antioxidant activity assays and cell culture studies were performed. Results:In vitro assessment in 4T1 (murine mammary carcinoma) and MCF-7 (human breast adenocarcinoma) cells revealed enhanced efficacy of the co-loaded SLNs as compared with free drugs and single drug-loaded SLNs. Increased apoptosis following treatment with DTX-ALA co-loaded SLN was also observed
Docetaxel and its nanoformulations: how delivery strategies could impact the therapeutic outcome?
(Future Science Group, 2020-09) Mittal, Anupama; Chitkara, Deepak
To overcome problems associated with current conventional formulations of DTX, efforts have been made to develop a variety of DTX-loaded nanosystems. These systems have improved water solubility, bioavailability and antitumor efficacy with a specific accumulation of drugs at tumor sites. Some of the novel DTX nanoformulations, which demonstrated exciting in vivo anticancer efficacy results, have grabbed the attention of pharmaceutical companies and successfully entered clinical trials
Drug-Loaded Polymeric Composite Skin Graft for Infection-Free Wound Healing: Fabrication, Characterization, Cell Proliferation, Migration, and Antimicrobial Activity
(Springer, 2012-06) Mittal, Anupama
The graft was fabricated using gentamicin and biomimetic microparticulate scaffolds in gelatin gel and characterized for biologically relevant properties like fluid uptake, evaporative water loss (EWL), water vapor transmission rate (WVTR), Young’s modulus and degradation. It was evaluated for drug release, cytocompatibility and antimicrobial efficacy against Staphylococcus aureus and Pseudomonas aeruginosa.